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Chemoradiation after Pancreaticoduodenectomy
for Pancreatic Adenocarcinoma is it of Proven Benefit?
ABSTRACT
Yeo, C. J., Abrams, R. A., Grochow, L. B., Sohn, T. A., Ord,
S. E., Hruban, R. H., Zahurak, M. L., Dooley, W. C.,
Coleman, J. A., Sauter, P. K., Pitt, H. A., Lilemoe, K. D.
and Cameron, J. L. (1997) Pancreaticoduodenectomy for
pancreatic adenocarcinoma: postoperative adjuvant che-
moradiation improves survival. Annals of Surgery; 225,
621-636.
Objective: This study was designed to evaluate
prospectively survival after pancreaticoduodenect-
omy for pancreatic adenocarcinoma, comparing two
different postoperative adjuvant chemoradiation
protocols to those of no adjuvant therapy.
Summary Background Data: Based on limited data
from the Gastrointestinal Tumor Study Group.
Adjuvant chemoradiation therapy has been recom-
mended after pancreaticoduodenectomy for adeno-
carcinoma of the head, neck, or uncinate process of
the pancreas. However, many patients continue to
receive no such therapy.
Methods: From October 1991 through September
1995, all patients with resected, pathologically
confirmed adenocarcinoma of the head, neck, or
uncinate process of the pancreas were reviewed by a
multidisciplinary group (surgery, radiation oncol-
ogy, medical oncology, and pathology) and were
offered three options for postoperative treatment
after pancreaticoduodenectomy: 1) standard therapy:
external beam radiation therapy to the pancreatic
bed (4000-4500 cGy) given with two 3-day fluorour-
acil (5-FU) courses and followed by weekly bolus 5-
FU (500mg/m
2 per day) for 4 months: 2) intensive
therapy: external beam radiation therapy to the
pancreatic bed (5040-5760cGy) with prophylactic
hepatic irradiation (2340-2700 cGy) given with and
followed by infusional 5-FU (200mg/m
2 per day)
plus leucovorin (5mg/m
2 per day) for 5 of 7 days for
4months: or 3) no therapy: no postoperative radia-
tion therapy or chemotherapy.
Results: Pancreaticoduodenectomy was performed
in 174 patients, with 1 in-hospital death (0.6%).
Ninety-nine patients elected standard therepy, 21
elected intensive therapy and 53 patients declined
therapy. The three groups were comparable with
respect to race, gender, intraoperative blood loss,
tumor differentiation, lymph node status, tumor
diameter, and resection margin status. Univariate
analyses indicated that tumor diameter <3cm,
intraoperative blood loss <700mL, absence of in-
traoperative blood transfusions, and use of adjuvant
chemoradiation therapy were associated with sig-
nificantly longer survival (p < 0.05). By Cox propor-
tional hazards survival analysis, the most powerful
predictors of outcome were tumor diameter, intrao-
perative blood loss, status of resection margins, and
use of postoperative adjuvant thereapy. The use of
postoperative adjuvant chemoradiation therapy was
a predictor of improved survival (median survival,
19.5months compared to 13.5 months without ther-
apy; p 0.003). The intensive therapy group had no
survival advantage when compared to that of the
standard therapy group (median survival, 17.5
months vs. 21 months, p not significant).
Conclusions: Adjuvant chemoradiation therapy sig-
nifcantly improves survival after pancreaticoduode-
nectomy for adenocarcinoma of the head, neck, or
uncinate process of the pancreas. Based on these
survival data, standard adjuvant chemoradiation
therapy appears to be indicated for patients treated
by pancreaticoduodenectomy for adenocarcinoma of
the head, neck, or uncinate process of the pancreas.
Intensive therapy conferred no survival advantage
over standard therapy in this analysis.
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PAPER DISCUSSION
Some ten years have elapsed since the Gastro-
intestinal Tumor Study Group recommended
adjuvant chemoradiation therapy following pan-
creaticoduodenectomy for pancreatic adenocar-
cinoma [1,2]. There has been a reluctance,
however, to accept the results of the study
which demonstrated a small survival advantage
for the treated patients. There was considerable
scepticism regarding the significance of the
findings of the study which recruited only 43
patients from a number of centres over an eight-
year period. Whilst the results of other larger
randomised studies are awaited, the surgeon has
to look for guidance from institutions such as
Johns Hopkins, where large numbers of patientsHPB INTERNATIONAL 199
have been managed with aggressive surgical
and oncological protocols.
That surgery alone is insufficient to confer
long-term survival benefit, is evident from this
[3] and other recent papers from this group
[4,5]. The median survival of the 174 patients
undergoing pancreaticoduodenectomy was 19
months and actuarial survival was 36% at two
years. The need to consider adjuvant treatment
is emphasised by the fact that 51 (29%) of
patients had positive resection margins and 130
(75%) had lymph nodes involved by tumour.
The authors can justify their aggressive surgical
approach based on a low complication rate
(36%), a low re-operation rate (3%) and an in-
hospital mortality of 0.6%. It is notable, however,
that the 62 patients who developed complica-
tions had a median survival of 15months as
opposed to 20months for the 112 patients
who were complication-free. Other factors
influencing survival included intra-operative
blood loss, transfusion requirement and
tumour diameter. In trying to establish whether
chemoradiation after pancreaticoduodenectomy
is of proven benefit, it is difficult to accept that
these factors did not have a bearing on survival.
In the four-year study period, only patients
who were deemed to have recovered satisfacto-
rily from pancreaticoduodenectomy by post-
operative day 60 were encouraged to accept
standard therapy or intensive therapy with
chemoradiation. On this basis it is difficult to
accept that the results of the two therapy groups
can be usefully compared with the group of
patients who did not receive post-operative
chemoradiation. Median survival for the 53
patients who received no therapy was
13.5 months and compared unfavourably to the
21months survival in the 99 patients who
received conventional therapy comprising ex-
ternal beam radiation (EBR) to the pancreatic
bed (4000-4500 cGy) and 5-Fluorouracil for four
additional months. It was perhaps disappointing
to find that the 21 patients who elected to receive
more intensive EBR to the liver and pancreas,
along with 5-Fluorouracil combined with leu-
covorin, did not appear to benefit, with a
median survival of 17.5months. It is a major
concern of this non-randomised study that
survival advantage was apparent within the
first few months of follow-up, with approxi-
mately 95% of all patients receiving adjuvant
therapy being alive at six months, compared to
approximately 70% in the non-adjuvant group.
Further analysis of the data shows that the no
therapy group were significantly older, had a
significantly longer post-operative stay in hos-
pital and experienced significantly more com-
plications than either of the two treatment
groups. To be fair to the Baltimore group, their
multivariate analysis did identify adjuvant
therapy as a significant predictor of outcome.
However, it could be argued that this conclusion
was inevitable, given the patient and clinical
bias towards selection of treatment. The lack of
any quality of life assessment is an omission in a
group of patients in whom the poor survival
prospects render this a major consideration.
The results from this report may not readily
lead other clinicians to agree with the authors’
conclusions that standard 5-Fluorouracil-based
chemotherapy combined with external beam
radiation therapy appears to be indicated after
surgery in patients undergoing pancreaticoduo-
denectomy for pancreatic adenocarcinoma.
There is a need for more information and the
results of randomised studies are eagerly
awaited.
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Intractable Ascites Management: The Role
of Side-to-Side Portacaval Shunt
ABSTRACT
Orloff, M. J., Orloff, M. S., Orloff, S. L. and Girard B.
(1997) Experimental, clinical and metabolic results of side-
to-side portacaval shunt for intractable cirrhotic ascites.
The American College of Surgeons; 184, 557-570.
Background: Intractable ascites, refractory to medi-
cal therapy, occurs in approximately 10 percent of
patients with ascites from cirrhosis and is almost
always fatal. Sinusoidal hypertension resulting from
hepatic venous outflow obstruction plays a primary
role in the pathogenesis of cirrhotic ascites and
provides the rationale for decompression of the liver
by side-to-side portacaval shunt in treatment of
intractable ascites. This report presents the experi-
mental basis for the use of side-to-side shunt and
long-term results of a prospective study in 34
selected patients with intractable cirrhotic ascites.
Study Design: In the experimental studies, hepatic
venous outflow obstruction and massive ascites
were produced in dogs by ligation of the hepatic
veins, and the effect of portacaval shunts on ascites,
thoracic duct lymph flow, and aldosterone secretion
were measured. In the clinical study, 34 carefully
selected patients with cirrhosis (91 percent alcoholic)
and truly intractable ascites (failure of medical
therapy for 5 to 24 months) underwent side-to-side
portacaval shunt. The effects on ascites, survival,
metabolic abnormalities, and quality of life were
studied prospectively during follow-up that was
longer than 5 years in all but two patients. Quan-
titative Child’s risk classes in percent of patients
were A in 0, B in 68 and C in 32.
Results: In the experimental studies, side-to-side
portacaval shunt permanently relieved severe as-
cites, reduced the 13-fold increase in thoracic duct
lymph flow rate to almost normal,and abolished the
aldosterone hypersecretory response to minimal
hepatic venous outflow obstruction. End-to-side
portacaval shunt was much less effective. In the
clinical study, side-to-side portacaval shunt reduced
mean portal vein-inferior vena cava pressure gradi-
ent from 282mm saline to 4mm and permanently
relieved all patients of ascites without subsequent
requirement of diuretic therapy. Two patients who
died of hepatoma, and one who died of heart failure
developed terminal ascites. Thirty-day mortality rate
was 6 percent and long-term survival rates at 5, 10
and 15 years were 75 percent, 74 percent and 73
percent. In metabolic studies, side-to-side shunt pro-
duced marked diuresis and natriuresis and abol-
ished hypersecretion of aldosterone. Quality of life
was generally improved as a result of a low inci-
dence of recurrent portal-systemic encephalopathy
(6 percent), abstinence from alcohol in 91 percent,
improvement in liver function in 81 percent, and
improvement in Child’s risk class. The portacaval
anastomosis remained permanently patent in every
patient.
Conclusions: Side-to-side portacaval shunt is very
effective treatment of intractable ascites from cir-
rhosis. Our results are attributable to careful selec-
tion of patients, an organized system of care, and a
program of rigorous, lifelong follow-up that empha-
sizes abstinence from alcohol and dietary protein
restriction. (J. Am. Coll. Surg., 1997; 184 557-570).
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PAPER DISCUSSION
The development of refractory ascites in cirrho-
tic patients is relatively low. It is accepted that
approximately 10 percent of the patients with
ascites either do not respond to diuretic therapy
or develop diuretic-induced complications that